Product Data Sheet

Product Name: SSR504734
Cat. No.: GC67871

Chemical Properties

Cas. No.	615571-23-8		
Formula	$C_{20}H_{21}Cl_2F_3N_2O$	M.Wt	433.29
Solubility	DMSO : 100 mg/mL (230.79 mM; Need ultrasonic)	Storage	4°C, away from moisture and light
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure	SSR504734		

Background

SSR504734 is an orally active, selective and reversible inhibitor of human, rat, and mouse **GlyT1** (**IC_{50}**=18, 15, and 38 nM, respectively). SSR504734 shows anti-schizophrenia, anti-anxiety and anti-depression activities[1].

SSR504734 (15 nM-86 μM; 10 min) inhibits glycine uptake in human SK-N-MC and rat C6 cells[1].

Cell Viability Assay[1]

Cell Line:	Human neuroblastoma (SK-N-MC) and rat astrocytoma (C6) cells
Concentration:	15 nM-86 μM
Incubation Time:	10 min

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Result:	Showed IC_{50} values of 18 and 15 nM for human SK-N-MC and rat C6 cells, respectively.

SSR504734 (i.p. and p.o.; 1-100 mg/kg; once) treatment shows good oral bioavailability[1].
SSR504734 (i.p.; 30 mg/kg; once) induces a rapid and significant decrease of specific glycine uptake[1].
SSR504734 (i.p.; 10 mg/kg; once) increases extracellular levels of Glycine in the prefrontal cortex (PFC) of freely moving rats[1].

Animal Model:	Male Sprague-Dawley rats[1]
Dosage:	1-100 mg/kg
Administration:	Intraperitoneal injection and oral gavage.; 1-100 mg/kg; once
Result:	Showed ID_{50} values of 5.0 and 4.6 mg/kg for i.p. and p.o. treatments, respectively.
Animal Model:	Male Sprague-Dawley rats[1]
Dosage:	30 mg/kg
Administration:	Intraperitoneal injection; 30 mg/kg; once
Result:	Maintained at about 80% inhibition from 1 to 7 h after administration.
Animal Model:	Male Sprague-Dawley rats[1]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; 10 mg/kg; once
Result:	Produced a rapid and sustained increase in PFC extracellular levels of glycine.

[1]. Ronan DepoortÈre, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new

type of antipsychotic. Neuropsychopharmacology. 2005 Nov;30(11):1963-85.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA